Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03307876Completed

Injection of an Autologous A2M Concentrate Alleviates Back Pain in FAC-positive Patients

Role: lead

NCT01613833Suspended

Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints

Role: lead

NCT01079026Completed

Outcome After Lumbar Epidural Steroid Injection

Role: lead

NCT01006278Completed

Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee

Role: lead

NCT00836966Completed

Sampling Biomarkers in Meniscus Injury to the Knee

Role: lead

All 5 trials loaded